Pfizer Deutschland

What Pfizer Deutschland does

Pfizer Deutschland is the German subsidiary of Pfizer Inc. (NYSE: PFE), operating through two principal entities: Pfizer Pharma GmbH, headquartered in Berlin and responsible for the German commercial business, and Pfizer Manufacturing Deutschland GmbH, headquartered in Freiburg, which operates one of the company's largest and most strategically important manufacturing footprints in Europe. The subsidiary employs 10,000+ people in Germany, with roughly 7,000 in production roles, and its infrastructure has been positioned as the global production hub for Pfizer's COVID-19 oral antiviral treatment (Paxlovid) and as the global vaccine distribution hub for the Pfizer-BioNTech COVID-19 vaccine (Comirnaty) out of Karlsruhe. The German operations also invest in next-generation manufacturing, including a €300M+ High-Containment Factory at Freiburg opened around 2022 for biologic and high-potency API production, and participate in Pfizer's broader research collaborations including the BioNTech mRNA partnership originally signed in 2018 and materially expanded in 2020.

The subsidiary's core business model inherits the parent's pharmaceutical revenue mechanics: it sells patented, regulator-approved medicines and vaccines into the German healthcare system (statutory health insurance, hospitals, pharmacies, and physicians) at negotiated reimbursement prices, and generates additional revenue through transfer pricing on manufacturing output shipped to other Pfizer entities for global distribution. Its product portfolio spans primary care, oncology, vaccines, inflammation & immunology, and rare disease therapeutics, including oncology assets acquired through the Seagen transaction in 2023. The subsidiary benefits from Pfizer's enterprise-level AI and computational biology investments (IBM Watson for Drug Discovery, spatial biology research) and from the parent's sustainability commitments, including a corporate Net Zero target by 2040. As a wholly-owned subsidiary, Pfizer Deutschland does not publish standalone revenue and is not separately rated, but its operational footprint, regulatory licenses, and strategic hub designation make it a critical node in Pfizer's global value chain.

Name

Pfizer Deutschland

Legal name

Pfizer Pharma GmbH

Website

https://pfizer.de

Company type

Private

Founded year

1849

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Pfizer Deutschland is the German subsidiary of Pfizer Inc., operating Berlin-based commercial operations and one of Pfizer's largest global manufacturing and vaccine distribution hubs in Freiburg and Karlsruhe, with 10,000+ employees serving the German healthcare market and global supply chain.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Hospital & Health-System Pharmaceutical Distributors (HLAIAJAD), Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG), Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

• Pharmaceutical research
• Prescription medicines
• Vaccine development
• Oncology therapies
• Biologics manufacturing

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Prescription Pharmaceutical Products: Pfizer generates the majority of revenue from the sale of prescription medicines across its therapeutic areas including oncology, infectious diseases (including COVID-19 antivirals), cardiovascular/metabolic diseases, rare diseases, inflammatory diseases, and vaccines. Products are sold through direct field sales, inside sales, pharmacy distribution channels, and hospital pharmacy channels in Germany.
2. Vaccines: Pfizer commercializes vaccines including the COVID-19 mRNA vaccine (Comirnaty, developed with BioNTech) and other preventive vaccines. The vaccines business is a significant revenue driver, with the Freiburg site serving as the global distribution hub for COVID-19 vaccine supply.
3. Manufacturing & Production Services: Pfizer Manufacturing Deutschland GmbH operates production facilities in Freiburg for pharmaceutical manufacturing of sterile injectables, oral solid dosage forms, and high-containment products. The site serves global supply for COVID-19 oral treatment and other innovative medicines.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels7 records

Core offering

Pfizer Deutschland is the German subsidiary of Pfizer Inc., operating as a research-based pharmaceutical company that develops, manufactures, and distributes prescription medicines and vaccines across therapeutic areas including oncology, infectious diseases (including COVID-19), cardiovascular/metabolic diseases, rare diseases, inflammatory diseases, and vaccines. The company operates major pharmaceutical manufacturing facilities in Freiburg (with Pharma 4.0 high-containment and continuous manufacturing capabilities) and distributes its products exclusively through hospital pharmacies, hospital-serving pharmacies, and pharmaceutical wholesale channels serving public pharmacies across Germany.

Product overview

Pfizer Deutschland is the German subsidiary of Pfizer Inc., one of the world's largest pharmaceutical companies with 175 years of history. The company operates as a research-focused pharmaceutical company developing and manufacturing innovative medications and vaccines across multiple therapeutic areas including oncology, infectious diseases (COVID-19, antibiotics), rare diseases, inflammatory diseases, cardiovascular/metabolic diseases, and vaccines. The product portfolio centers on prescription pharmaceuticals, with key products including the BioNTech/Pfizer COVID-19 vaccine (Comirnaty) and oral COVID-19 treatment, antibiotic medications (Terramycin, Vibramycin, Diflucan), and cancer therapies. The company maintains manufacturing facilities in Freiburg (main production site for tablets and capsules including COVID-19 medications) and Berlin (headquarters), with distribution through Karlsruhe. In 2023, Pfizer expanded its oncology portfolio through the $43 billion acquisition of Seagen, acquiring antibody-drug conjugate technologies. Digital offerings include the PfizerPro portal for medical professionals and a Product Finder for patient information. The Freiburg site represents one of the world's most modern pharmaceutical production facilities with High-Containment capabilities (opened 2022, €300+ million investment).

Differentiator

Problem solved

Functional benefit

Brands

• PfizerPro: Portal for medical professionals containing comprehensive information about Pfizer products and therapy areas.

Products and services

• COVID-19 Vaccine (Comirnaty) mRNA-based COVID-19 vaccine developed in partnership with BioNTech, providing protection against SARS-CoV-2 infection for healthcare providers, physicians, and patients. BioNTech holds the marketing authorization holder position and marketing rights for COMIRNATY in Germany.
• COVID-19 Oral Antiviral Treatment Oral antiviral medication for the treatment of COVID-19, manufactured at the Freiburg site in Germany for global distribution. Helps reduce severe disease progression and avoid hospitalizations from SARS-CoV-2 infection.
• Oncology Medications (ADC Portfolio) Innovative cancer medications and therapies including antibody-drug conjugate (ADC) technologies from Seagen, aimed at earlier detection and successful treatment of cancer. Sold through hospital pharmacy distribution channels for oncology injectables and oral therapies.
• Vaccines Portfolio Vaccines and immunization products across multiple disease areas, including the COVID-19 mRNA vaccine (with BioNTech) and the development of mRNA-based influenza vaccines. Includes the vaccine portfolio acquired from Baxter International Inc. in 2014 ($635 million).
• Antibiotics and Anti-infectives Portfolio of antibiotic and anti-infective medications addressing infectious diseases and antibiotic resistance, including legacy products such as Terramycin (Oxytetracycline, first Pfizer-labelled drug, 1950), Vibramycin (Doxycycline, 1967), Diflucan (Fluconazole, antimycotic), and Vfend (Voriconazole, launched 2002).
• Rare Disease Treatments Medications targeting rare diseases, addressing the needs of approximately 4 million people in Germany affected by rare conditions. Expanded through the 2022 acquisition of Global Blood Therapeutics Inc. (sickle cell disease).
• Cardiovascular and Metabolic Disease Medications Pharmaceuticals for cardiovascular and metabolic diseases, produced at the Freiburg manufacturing facility. Covers heart-circulatory conditions and metabolic disorders for hospital and public pharmacy distribution.
• Inflammatory Disease Treatments Medications addressing inflammatory diseases, expanded through the 2022 acquisition of Arena Pharmaceuticals for immuno-inflammatory therapies. Part of Pfizer's core therapeutic research and development areas.
• Migraine Therapy (Biohaven) Innovative migraine therapy for acute treatment and prevention of episodic migraine in adults, acquired through the 2022 Biohaven Pharmaceutical acquisition, adding a differentiated neurology product to Pfizer's portfolio.
• RSV Antiviral Therapeutics (ReViral) Antiviral therapeutics targeting Respiratory Syncytial Virus (RSV), acquired via the 2022 ReViral acquisition, broadening Pfizer's infectious disease portfolio.
• Toviaz (Fesoterodinfumarat) Prescription medication for the treatment of symptoms of overactive bladder in adults.

Quantifiable outcome

• Pfizer produced five times more penicillin than originally expected within four months in 1941, becoming the world's largest manufacturer of the drug.
• +3 more outcomes

Segments4 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

24 partnerships are on record, tiered flagship, minor and core.

• SeagenflagshipStrategic or Co-development Partner · 1 January 2023Pfizer announced the acquisition of Seagen, a cancer specialist, for $43 billion in 2023. With this acquisition, Pfizer expanded its portfolio with world-leading technologies in the field of antibody-drug conjugates (ADC), significantly strengthening its oncology franchise.
• Arrea PharmaceuticalsminorStrategic or Co-development Partner · 1 January 2022In 2022, Pfizer acquired Arrea Pharmaceuticals, a company developing innovative therapies for the treatment of various immunoinflammatory diseases, expanding its pipeline in this therapeutic area.
• ReViralminorStrategic or Co-development Partner · 1 January 2022In 2022, Pfizer acquired ReViral, a biopharmaceutical company focused on discovering and developing novel antiviral therapeutics targeting Respiratory Syncytial Virus (RSV), broadening its infectious disease portfolio.
• Biohaven Pharmaceutical Holding Company Ltd.minorStrategic or Co-development Partner · 1 January 2022In 2022, Pfizer acquired Biohaven Pharmaceutical Holding Company Ltd., which had developed an innovative migraine therapy for acute treatment and prevention of episodic migraine in adults, adding a differentiated neurology product to Pfizer's portfolio.
• Global Blood Therapeutics Inc.minorStrategic or Co-development Partner · 1 January 2022In 2022, Pfizer acquired Global Blood Therapeutics Inc., a biopharmaceutical company researching treatments for patients with limited therapeutic options, including patients with sickle cell disease, expanding Pfizer's presence in rare hematological diseases.
• Accord for a Healthier World (45 Lower-Income Countries)flagshipStrategic or Co-development Partner · 1 January 2022The 'Accord for a Healthier World' initiative offers Pfizer's patented medicines and vaccines at cost in 45 lower-income countries, aiming to close the health equity gap. The initiative represents a fundamentally new approach to sustainable global health access.
• BioNTechflagshipStrategic or Co-development Partner · 1 January 2020In December 2020, a nearly 91-year-old British woman became the first person in the world to receive a COVID-19 vaccination with the BioNTech/Pfizer mRNA vaccine (COMIRNATY). Beyond developing the vaccine, Pfizer contributed an oral treatment option to the fight against the pandemic, manufactured in Freiburg for the global market.
• BioNTechcoreStrategic or Co-development Partner · 1 January 2018Pfizer and BioNTech entered into a collaboration for the development of mRNA-based influenza vaccines. This partnership built the foundation for the subsequent COVID-19 vaccine collaboration launched in 2020.
• Watson Health (IBM)coreTechnology or Integration · 1 January 2016Watson Health and Pfizer announced a collaboration using IBM Watson for Drug Discovery to accelerate Pfizer's immuno-oncology research. Pfizer was one of the first companies worldwide to use Watson for Drug Discovery and the first to customize the cloud-based cognitive tool to its needs. Watson's machine learning and natural language processing support the identification of new drug targets, combination therapies, and patient selection strategies.
• HospiracoreStrategic or Co-development Partner · 1 January 2015Pfizer completed the acquisition of Hospira in 2015 for approximately $3 billion, expanding its GEP (Global Established Products) sterile injectable generics business with a growing revenue stream and platform for growth, including biosimilars.
• Baxter International Inc. (Vaccine Portfolio)minorStrategic or Co-development Partner · 1 January 2014Pfizer announced a definitive agreement to acquire Baxter International Inc.'s vaccine portfolio for $635 million. As part of the transaction, Pfizer also acquired part of Baxter's facility in Orth, Austria, where these vaccines are manufactured.
• WyethflagshipStrategic or Co-development Partner · 1 January 2009On October 15, 2009, Pfizer acquired Wyeth for approximately $68 billion, creating a company with a broad portfolio of products and therapies affecting patients' and consumers' lives every day and at every stage of life. The acquisition expanded Pfizer's vaccine, biotechnology, and consumer healthcare businesses significantly.
• Private AccessminorOthers · 1 January 2009Pfizer partnered with Private Access, an innovator in privacy-enabled search technology, to create a new online community to raise awareness of clinical trials and increase participation, addressing the key bottleneck of patient enrollment in medical research.
• Claris Lifesciences Ltd. and Aurobindo Pharma Ltd.minorStrategic or Co-development Partner · 1 January 2009Pfizer concluded key licensing agreements with two India-based pharmaceutical companies — Claris Lifesciences Ltd. and Aurobindo Pharma Ltd. — to improve the availability of medicines for underserved populations worldwide and to supplement Pfizer's portfolio of proven products with new non-Pfizer medicines.
• Grameen HealthminorStrategic or Co-development Partner · 1 January 2008Grameen Health, a subsidiary of Grameen Bank (the 2006 Nobel Peace Prize laureate for poverty alleviation), partnered with Pfizer to identify sustainable models for healthcare delivery in developing countries, leveraging Grameen's microfinance community network.
• Medivation (Dimebon)minorStrategic or Co-development Partner · 1 January 2008Pfizer entered into an agreement with Medivation to develop and commercialize the investigational drug Dimebon for the treatment of Alzheimer's and Huntington's disease, expanding Pfizer's neuroscience pipeline.
• Corning Incorporated (Valor Glass)coreStrategic or Co-development Partner · 1 January 2007Pfizer and Corning Incorporated partnered to introduce Valor Glass pharmaceutical packaging, a revolutionary solution offering superior chemical resistance, strength, and damage resistance for injectable drug vials and cartridges. The collaboration combined Pfizer's and Merck's pharmaceutical formulation expertise with Corning's glass science and precision forming capabilities, improving drug storage, delivery, and patient access to modern medicines.
• Global Health Fellows ProgramminorStrategic or Co-development Partner · 1 January 2003CEO Hank McKinnell announced the Global Health Fellows Program, calling on Pfizer colleagues to volunteer for up to six months in developing countries on HIV/AIDS projects. The first 18 Global Health Fellows were deployed in 2003.
• Pfizer Foundation (International HIV/AIDS Health Literacy Grants Program)minorStrategic or Co-development Partner · 1 January 2002The Pfizer Foundation launched a three-year initiative providing grants to support training and capacity building for HIV/AIDS in developing countries through the International HIV/AIDS Health Literacy Grants Program, with twelve organizations receiving grants.
• Academic Alliance for AIDS Care and Prevention (Makerere University, Uganda)minorStrategic or Co-development Partner · 1 January 2001In July 2001, CEO Hank McKinnell announced funding for the construction of a regional treatment and training center on the campus of Makerere University in Kampala, Uganda, as part of the Academic Alliance for AIDS Care and Prevention. The Infectious Diseases Institute opened in 2004 as a state-of-the-art facility for education and treatment of HIV/AIDS and other infectious diseases, with Pfizer and the Pfizer Foundation contributing over $15 million through a public-private partnership.
• South African Ministry of Health (Diflucan Partnership Program)minorGTM or Marketing Partner · 1 January 2000Pfizer and the South African Ministry of Health signed a Memorandum of Understanding to establish the Diflucan Partnership Program, providing Pfizer's antifungal medication Diflucan to address HIV/AIDS-related opportunistic infections in South Africa.
• Edna McConnell Clark Foundation (International Trachoma Initiative)minorStrategic or Co-development Partner · 1 January 1998Pfizer and the Edna McConnell Clark Foundation jointly founded the International Trachoma Initiative (ITI) to support the eradication of trachoma, a bacterial disease of the conjunctiva and cornea, one of the leading causes of preventable blindness.
• Cluster Gesundheitswirtschaft Berlin-BrandenburgcoreStrategic or Co-development PartnerPfizer is part of the Cluster Gesundheitswirtschaft Berlin-Brandenburg, a healthcare industry cluster aiming to develop Berlin-Brandenburg as a top location for life sciences, healthcare, and economic growth. Pfizer participates in the Masterplan 'Berlin-Brandenburg – Zukunft der Gesundheit' (2020), contributing to the region's health innovation ecosystem.
• Various German Industry Associations (vfa, BDI, Bitkom, BMC, FSA, GWD, LAWG, BWiMin, etc.)minorStrategic or Co-development PartnerPfizer is a member of and actively participates in German industry associations including the Verband Forschender Arzneimittelhersteller (vfa), Bundesverband der Deutschen Industrie (BDI), Bitkom, BMC, FSA, Grüner Wirtschaftsdialog (GWD), LAWG, American Chamber of Commerce, and others, engaging in policy advocacy and industry collaboration.

Scale indicators9 records

Recent moves11 records

Expansion highlights5 records

Market position

Competitive moat5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pfizer
• Xx.com/pfizer_de

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pfizer Deutschland